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MAGISTRAL 
PREPARATIONS 
INTRODUCTION 
• Pharmacists are responsible for ensuring that drug use is safe 
and effective. 
• Wherever practicable, licensed medicines are used and 
represent the ‘gold standard’ for quality, safety and efficacy. 
There are, however, circumstances in which there is no 
licensed medicine that fully meets the clinical needs of a 
particular patient or patients. In these circumstances it is 
sometimes necessary for the pharmacist to extemporaneously 
prepare a limited quantity of a custom-made medicine for a 
specific patient. 
•  Oral liquid medicines are commonly extemporaneously 
prepared because of a relative lack of licensed formulations for 
groups such as the young or elderly who are unable to swallow 
tablets or capsules, or for whom the required dose is less than a 
single tablet/ capsule. 
INTRODUCTION 
• Extemporaneous preparation remains one of the highest 
risk preparative activities carried out in the pharmacy, as 
the risks of unlicensed medicines are combined with 
inherent risks associated with the pharmaceutical 
compounding process  
• In addition, extemporaneously prepared medicines are 
commonly given to some of the most vulnerable patients 
in hospitals and communities (e.g. neonates, children, 
elderly patients, stroke victims, patients with feeding 
tubes in situ).  
• These vulnerable patients are often not capable of alerting 
carers or staff to any adverse drug events they may be 
experiencing. 
INTRODUCTION 
• There have been a number of reports of errors associated with 
the use of extemporaneously prepared medicines, resulting in 
serious harm to patients. 
• The most notable incident in recent UK history was the 
‘peppermint water case’, where the use of the wrong strength 
of chloroform water led to the death of a child.  
• This case highlighted the issues of toxic ingredients and 
calculation errors, particularly where the strength of one or 
more ingredients is stated in a historical or non-standard 
fashion.  
• Similar incidents have occurred in the USA, including the 
death of a child from a superpotent imipramine liquid, and 
another of a 5-year-old child who received a thousand-fold 
overdose of clonidine 
INTRODUCTION 
• Administration errors have also been reported, including 
five-fold, tenfold, hundred-fold or thousand-fold mistakes 
in calculating or measuring doses.  
• Some of these errors have been attributed to inadequate 
labeling (e.g. confusion between strengths expressed per 
mL or per 5 mL). 
• The relative lack of research and development work 
supporting these products is associated with the potential 
for formulation failure or poor dose uniformity, resulting 
in the risk of overdose or underdose.  
• The lack of high quality data to support historical 
formulae has been acknowledged by authors across the 
world 
INTRODUCTION 
• Even where a given formulation has been shown to achieve suitable 
physical, chemical and microbiological stability, the bioavailability 
and palatability of the preparation may be unproven.  
• Very few extemporaneous preparations are supported by any data to 
demonstrate a suitable absorption profile and/or bioequivalence with 
a licensed preparation.  
• Other issues include concerns about inadequate access to equipment 
and materials needed to provide a safe extemporaneous dispensing 
service and the highest possible quality products 
• There is therefore an identified need to investigate and improve the 
quality of formulation of the oral medicines currently prepared, with 
a view to offering further guidance to pharmacists in order to 
minimize risks to patient safety. 
PREPARATION 
• The preparation process includes all the practical procedures and processes required to 
extemporaneously prepare, package and label a medicine, ready for supply to a named patient. 
• Critical processes in the preparation of extemporaneous products should be identified using process 
mapping techniques.  
• Critical processes include the following: 
• * prescription verification 
• * worksheet and label generation 
• * assembly of components 
• * weighing 
• * measurement of liquids 
• * grinding tablets into uniform powders 
• * mixing 
• * reconciliation 
• * packaging and labeling. 
• Appropriate control measures should be implemented at all critical points in the process and should 
include a procedural check (independent, wherever possible) by a suitably trained person as a 
minimum.  
• These measures should be validated (in the case of reproducible or automated processes) or subject 
to competence assessment (in the case of operator dependent processes). 
PREPARATION 
• Prescription verification 
All prescriptions must be signed by an approved prescriber. 
Prescriptions should be clear, unambiguous and accurate. The 
medicine(s) and dose(s) selected must be appropriate to meet 
agreed therapeutic objectives. 
Pharmacists should ensure that medication errors do not occur 
from any cause, including as a result of prescribing, formulation 
or calculation errors. 
 It is the responsibility of the authorizing pharmacist to ensure 
that prescriptions are verified. 
PREPARATION 
• Prescription verification 
A written approved procedure should be in place for prescription 
verification which should include checks for the following where 
appropriate: 
* full signature of authorized prescriber and date 
* patient details (e.g. full name, hospital number, consultant, ward, date of 
birth, weight where appropriate). 
* correct dose calculation 
* administration details 
* compatibility with prescribed constituents 
* stability of formulation 
* correct presentation for intended route of administration 
* absence of contraindications, allergies or drug interactions. 
Records must indicate who carried out the verification of each prescription. 
These records should be retained for a period that is in accordance with 
legal requirements and with the local policy. 
PREPARATION 
• Documentation 
The relevant master document should be selected and a product 
specific worksheet and label should be prepared before starting 
preparation. 
Where a calculation is required, it should be independently 
checked by an appropriate second person wherever possible. 
The check should be performed prior to preparation to minimize 
the chance of product wastage. 
PREPARATION 
• Starting materials 
• All starting materials should be checked against the worksheet 
to ensure that the correct materials have been selected. 
• Ensure that all starting materials are either licensed or have 
been approved for use following a quality assessment. 
• The chemical and microbiological quality of any water used in 
preparations should be specified and monitored if taken from 
the mains or local water systems. Monitoring is not necessary 
if sterile bottled water for injections or irrigation is used.  
• Sterile bottled water should be given a maximum shelf-life of 
24 hours once opened, with its status clearly labeled. 
• Ensure that the starting materials are ‘in date’ at the time of 
production and for the duration of the product’s shelf-life. 
•  Check that containers are clean and fit for use. 
PREPARATION 
• Weighing 
• Before starting the process, ensure the weighing range of 
the balance is appropriate for the quantity of material to 
be weighed. 
• The balance should be leveled according to the leveling 
bubble (where appropriate) and should be protected from 
draughts and risk of other disturbance. 
• The balance should be checked regularly using 
appropriate weights and be re-calibrated if necessary.  
• Records of checks and calibrations should be maintained. 
• Where possible the balance should be linked to a printer 
so that a permanent record of the weight measured can be 
retained with the worksheet 
PREPARATION 
• Weighing 
• Record accurately the batch number and expiry date of the starting 
materials on the worksheet. 
• Check that the balance is weighing the correct units of weight 
(micrograms, milligrams, grams, kilograms, etc.). 
•  Before commencing weighing, the balance should be tarred. 
• Where possible, a second person should check that the correct 
materials and weights of material have been used and measured. 
• This should be recorded on the worksheet. 
• Common errors in weighing to look out for include: 
• * putting the decimal point in the wrong place (e.g. 14.4 g instead of 
1.44 g) 
• * reversing the order of digits (e.g. 15680 g instead of 15860 g) 
• * misreading double digits 14556 g instead of 14566 g). 
PREPARATION 
• Measurement of liquids 
• The measuring of all liquid starting materials should be 
undertaken in appropriate and validated measuring vessels 
wherever possible. 
•  In some cases the use of unvalidated devices may be 
appropriate (e.g. syringes for small volumes). 
• The selected measure should be appropriate for the volume of 
liquid required. 
•  Where possible, glass measures should be avoided to 
minimize the risk of undetected contamination with broken 
glass. 
•  When glass is used, it should be regularly inspected for chips 
and cracks and replaced as necessary. It is recognized that in 
some cases glass may be the container of choice (e.g. when 
measuring oils and solvents). 
PREPARATION 
• Crushing tablets 
• When tablets are used as a starting material for making a 
suspension, care should be taken to ensure they are 
ground to a fine uniform powder.  
• A lack of uniformity in particle size may have a 
detrimental effect on dose uniformity. 
•  Tablets should be ground to a powder using a pestle and 
mortar, and a check of powder uniformity should be made 
and documented on the worksheet 
PREPARATION 
• Mixing 
1. Powders 
Where two powders are to be mixed, the process should be undertaken in a 
way that will achieve homogeneity. This is commonly accomplished by 
triturating equal aliquots of the powders, mixing well between each 
addition, until the entire quantity of the bulk material has been incorporated 
2. Liquids 
Miscible liquids will eventually mix completely by diffusion. To speed up 
the 
process the liquids should be mixed using a stirring rod or paddle. Avoid 
the use of glass stirring rods or stainless steel stirring rods in glass 
containers, as this can increase the risk of contamination with glass 
fragments.  
Where powder is to be dissolved in or added to a liquid to make a solution 
or suspension, it should be added to the liquid slowly with continuous 
stirring to prevent it from aggregating. Once the powder is dissolved or 
evenly dispersed, the solution should be made up to the required volume. 
PREPARATION 
• Mixing 
3. Semi-solids 
The final product should always be uniform in appearance and 
consistency. 
Where a dispersion of particles or solution into a semi-solid is 
required (e.g. ointment, cream, paste), a small amount of the 
semi-solid should be mixed with the powder/liquid to form a stiff 
paste before incorporating the remainder of the vehicle, in small 
aliquots, to form a homogeneous product. 
Where a mechanical mixer is used to assist in the preparation of 
a semisolid product, consideration should be given to the 
optimum mixing period, as too short or too long a time may have 
detrimental effects on the final product 
PREPARATION 
• Packaging and labeling 
• The primary packaging for the product (e.g. bottle and closure) 
must be fit for purpose. It must adequately protect the product 
from the environment while being compatible with the 
product. 
• The physico-chemical properties of the drug and formulation 
should be considered when selecting the type of packaging. 
• * For medicines sensitive to light, a light-proof pack should be 
considered (e.g. opaque or amber bottle). 
• * When a medicine is sensitive to oxidation, a tight-fitting 
closure and impermeable pack is required. 
• * The potential for medicine loss by absorption and 
permeation, or leaching of additives from plastics needs to be 
considered for certain formulations (e.g. poorly soluble 
medicines formulated with solvents to improve drug 
solubility). 
PREPARATION 
• Packaging and labeling 
• Generally glass can be considered to be inert and can be 
universally used as a container for the vast majority of 
formulations (with the exception of some concentrates, 
e.g. sodium bicarbonate). 
• Labels should be clear and legible, and must comply with 
all the statutory and professional requirements.  
• The information on the label should reflect the product 
prepared, and should tie in with the master label on the 
worksheet. 
• Where possible the contents of the label should be 
independently checked against the worksheet and the 
prescription/requisition. 
Finding and choosing an appropriate 
formulation 
• As with clinical papers, the pharmacist must consider the quality of 
the evidence source and the overall appropriateness of the 
formulation. 
• Comprehensive data should include information on physical and 
microbiological stability, as well as chemical stability testing. In rare 
cases, a given formulation may also be supported by successful 
clinical outcome data. 
• When choosing a formulation, it is imperative to consider the holistic 
needs of the prospective patient. This includes decisions regarding 
the form, strength, viscosity and excipient content of any given 
formula.  
• For example, a formulation designed for use in adults may contain 
inappropriate excipients for use in a child, and a viscous suspension 
may not be suitable for administration via a nasogastric tube.  
• Furthermore, historical formulations may contain starting materials 
which are no longer considered to be appropriate (e.g. chloroform). 
Hints on choosing a formulation – things 
to consider 
1. Shelf-life 
• Given the risks associated with extemporaneous 
formulation, it is recommended that the shelf-life of any 
extemporaneous product should not exceed 28 days if 
preserved or 7 days if unpreserved.  
• In the absence of supporting data, a limited shelf-life 
should be assigned based on the risk assessment of the 
individual drug.  
• For drugs with narrow therapeutic indices, this may be as 
little as 2 or 3 days 
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